[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Madrigal Pharmaceuticals President and CEO William John Sibold reported a mix of equity grants and a small share sale. On March 4, 2026, he received 18,743 stock options and 14,995 restricted stock units, both granted at $0.0000 per share and scheduled to vest in installments through 2030 subject to continued service.

On March 6, 2026, 1,663 shares of common stock were sold at an average price of $431.94 per share. According to the disclosure, this sale was executed by Madrigal Pharmaceuticals on Sibold’s behalf solely to cover tax withholding obligations tied to restricted stock unit vesting and was automatic rather than at his discretion. After these transactions, he directly held 161,829 shares of common stock and 18,743 stock options.

Insider Trade Summary

Net Seller: 1,663 shares ($718,316)

Net Sell 3 txns

Insider Sibold William John

Role President and CEO

Sold 1,663 shs ($718K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,663	$431.94	$718K
Grant/Award	Stock Option (Right to Buy)	18,743	$0.00	--
Grant/Award	Common Stock	14,995	$0.00	--

Holdings After Transaction: Common Stock — 161,829 shares (Direct); Stock Option (Right to Buy) — 18,743 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sibold William John

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A(1)		14,995	A	$0	163,492	D
Common Stock	03/06/2026		S(2)		1,663	D	$431.94	161,829	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$434.8	03/04/2026		A		18,743		(3)	03/04/2036	Common Stock	18,743	$0	18,743	D

Explanation of Responses:

1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

2. This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

3. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MDGL CEO William John Sibold report on this Form 4?

William John Sibold reported a grant of 18,743 stock options, a grant of 14,995 restricted stock units, and the sale of 1,663 common shares by Madrigal Pharmaceuticals to cover tax withholding obligations related to restricted stock unit vesting.

How many Madrigal Pharmaceuticals (MDGL) shares did the CEO sell and at what price?

A total of 1,663 Madrigal Pharmaceuticals common shares were sold at an average price of $431.94 per share. The company executed this sale on William John Sibold’s behalf to satisfy tax withholding obligations from restricted stock unit vesting.

What equity awards did MDGL grant to CEO William John Sibold in March 2026?

On March 4, 2026, Madrigal Pharmaceuticals granted William John Sibold 18,743 stock options and 14,995 restricted stock units at $0.0000 per share. These awards vest over several years, subject to his continued service with the company on specified future vesting dates.

How do the new MDGL equity awards to the CEO vest over time?

The 14,995 restricted stock units vest in four equal 25% installments on March 4 of 2027, 2028, 2029, and 2030. The 18,743 stock options vest 25% on March 4, 2027, with 6.25% vesting at the end of each successive three-month period thereafter, contingent on continued service.

Was the MDGL CEO’s March 6, 2026 share sale discretionary or automatic?

The March 6, 2026 sale of 1,663 shares was automatic and executed by Madrigal Pharmaceuticals on William John Sibold’s behalf. It was specifically to cover tax withholding obligations from restricted stock unit vesting and was not carried out at his personal discretion.

How many Madrigal Pharmaceuticals (MDGL) shares does the CEO hold after these transactions?

Following the reported transactions, William John Sibold directly held 161,829 shares of Madrigal Pharmaceuticals common stock and 18,743 stock options. These figures reflect the impact of the March 4, 2026 grants and the March 6, 2026 tax-withholding share sale.